Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Misses Estimates By $0.54 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.54), FiscalAI reports.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP traded down $0.28 during mid-day trading on Thursday, hitting $3.72. 64,629 shares of the company’s stock were exchanged, compared to its average volume of 547,008. The company has a market cap of $69.38 million, a price-to-earnings ratio of -0.61 and a beta of 2.80. Corbus Pharmaceuticals has a fifty-two week low of $2.81 and a fifty-two week high of $12.88. The stock’s 50-day moving average is $5.99 and its 200-day moving average is $8.40.

Insider Activity at Corbus Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total value of $1,742,500.00. Following the completion of the transaction, the insider owned 1,919,971 shares in the company, valued at approximately $7,871,881.10. The trade was a 18.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CRBP shares. Wall Street Zen lowered Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Thursday, October 15th. Oppenheimer restated an “outperform” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Mizuho dropped their price objective on Corbus Pharmaceuticals from $24.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, September 14th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $38.14.

Key Stories Impacting Corbus Pharmaceuticals

These are some of the CRBP stories that stood out recently:

• Positive Sentiment: Mizuho maintained an “Outperform” rating despite trimming its price target to $23 from $24. That target remains well above the referenced share price of $3.69. TickerReport article
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $35 price target. It also raised its estimates for 2027 and 2028, projecting smaller losses than previously expected for those years. MarketBeat analyst coverage
• Negative Sentiment: HC Wainwright lowered estimates for Q4 2026 and full-year 2026, as well as 2029 and 2030, indicating larger expected losses in those periods. These revisions temper the optimism from its Buy rating and higher estimates for 2027–2028. MarketBeat analyst coverage

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.